ClinicalTrials.gg
Not yet recruitingNCT07714759Updated Nov 19, 2026

A Study Comparing Continuous Glucose Monitoring Augmented Nutritional Counseling and Standard of Care Treatment Strategies in a Three-Month Nutrition Intervention

An interventional study of Use of an unblinded CGM device in Obesity & Overweight, Obese Adolescents and Metabolic Abnormalities, sponsored by University of Florida. Not yet recruiting at 1 site in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Florida · Not applicable, Interventional, and Prevention

How we know

Updated Nov 19, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Obesity by University of Florida — 5 open to participants now, 6 under way, none of them phase 3. Obesity · University of Florida.

Planned enrollment
12th of 34
100 · median 55
Started
2026
with 1 other
No phase
29 of 37
5 open now
Registered
36th of 37
by date

Among the 37 studies in Obesity by University of Florida, this one is the 12th largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2026, is one of 29 with no phase, and was the 36th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 37 studies in Obesity by University of Florida are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Obesity by University of Florida, or all of them as a file.
02

Study summary

The objective of this project is to determine the feasibility of introducing CGMs to adolescent patients with obesity and pre-diabetes (Hemoglobin A1C: HbA1C between 5.7-6.5%) to determine whether their eating habits and subsequent glucose profiles are modified by the timely awareness of glucose excursions above the diabetes threshold of 200 mg/dl.

Read the detailed description

Building on prior UF protocols and national ORBIT-model guidance for early-phase behavioral-treatment development, this study represents a Phase I/IIa feasibility and signal-of-efficacy trial. The study is a comparison of food choice and decision making between a NO CGM group and a Open-label CGM group. Several bio markers are used to determine the consequences of nutritional choices. This information is used in nutritional counselling sessions.

03

Conditions studied

  • Obesity & Overweight
  • Obese Adolescents
  • Metabolic Abnormalities

Keywords

  • continuous glucose monitor
  • obesity
  • overweight
  • Metabolic abnormality
04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 13-17 years.
  • ≥ 95 percentile
  • BMI >85th and BMI \< 95th percentile for age and sex (CDC growth charts) if the risk factors below are present: Family history of type 2 diabetes in first or second degree relative:

    • Race/ethnicity Native American, African American, Latino, Asian American, Pacific Islander
    • Signs of insulin resistance or conditions associated with insulin resistance (acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary syndrome, or small-for-gestational-age birth weight)
    • Maternal history of diabetes or gestational diabetes mellitus (GDM) during the child's gestation
  • Receiving care through HCN for pediatric or family medicine clinics.
  • No structured nutritional intervention in the past 3 months.
  • Parent/guardian able to provide and child able to assent.
  • Family has access to a smartphone or is willing to use a study-provided device for CGM viewing and communication.
  • Willingness to comply with study visits, CGM wear, and laboratory testing.

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation:

  • Diabetes by history or ≥ 6.5 % in the medical record or at screening.
  • Unable or unwilling to provide consent or participate fully in study activities.
  • Conditions predisposing to diabetes or altering normal pubertal development.
  • Current or planned use of medications affecting glucose dynamics, including:

    o Insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, metformin, or other glucose-lowering or weight-loss medications within 6 weeks prior to enrollment or planned during the study period.

  • Known syndromic or monogenic obesity.
  • Blood disorders that impact HbA1c interpretation (e.g., anemia, and variants).
  • Major systemic organ disease (renal, hepatic, or cardiac).
  • History or planned bariatric surgery.
  • Current pregnancy or plans for pregnancy during the study.
  • Use or planned use of GnRH agonists, estrogen, or testosterone.
  • Non-English- or non-Spanish-speaking individuals, as validated questionnaires are available only in these languages.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Open CGM use

    Use of a continuous glucose monitor where the patient can see all of their blood glucose data

    Device: Use of an unblinded CGM device

  • No intervention
    No CGM Use

    Standard of care treatment with no CGM use

Interventions

  • DeviceUse of an unblinded CGM device

    Open use of CGM device where patients can see their blood glucose values.

06

What researchers measure

Primary outcomes

  1. Total caloric intake

    Total caloric intake as assessed from a validated 24-hour Dietary Recall

    Time frame: Baseline; 3 Months

  2. Total grams of carbohydrates from sugar

    Total grams of carbohydrates from sugar in food as assessed from a validated 24-hour Dietary Recall

    Time frame: Baseline; 3 Months

Secondary outcomes

  1. 5-point Likert scale Questionnaire of child food understanding

    Results from a questionnaire assessing the child's understanding of food on a 5-point likert scale

    Time frame: Baseline; 3 Months

  2. Metabolic outcome - Difference in Hba1c

    Difference in Hba1c, tested per standard of care

    Time frame: Baseline; 3 Months

  3. Metabolic outcome - Difference in BMI Z score

    Difference in BMI Z score, per standard of care

    Time frame: Baseline; 3 Months

  4. Metabolic outcome - Difference in complete metabolic panel

    Difference in complete metabolic panel between baseline and 3 months, per standard of care

    Time frame: Baseline; 3 Months

  5. Differences in Fitness assessment scores

    Difference in Fitness Assessment scores using an already published fitness assessment testing battery given to each patient

    Time frame: Baseline; 3 Months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 8 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 20, 2026
StartEst.
Dec 2026was Aug 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Dec 2026
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Aug 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07714759
Collaborators
Healthcare Network, Collier County Health Services
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Dec 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Angelina Bernier, MD
Contact
angelina@ufl.edu
508-558-0475
Salvatore Anzalone, MD
Contact
sanzalone@healthcareswfl.org
610-587-1010

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion